What topical medication can be used to treat molluscum contagiosum lesions?

Topical Treatment for Molluscum Contagiosum

For molluscum contagiosum lesions, 10% potassium hydroxide applied once daily is the most evidence-based topical medication, demonstrating superior efficacy to placebo with better tolerability than higher concentrations. 1, 2

Primary Topical Treatment Options

Potassium Hydroxide (First-Line)

• 10% potassium hydroxide solution applied once daily achieves complete lesion clearance in 58.8% of patients, significantly superior to placebo (18.8%, P=0.03) 2
• Apply daily until complete clearing of lesions, with maximum duration of 60 days 2
• Better tolerated than 15% concentration while maintaining comparable efficacy (64.3% clearance with 15% vs 58.8% with 10%) 2
• Significantly reduces total lesion count compared to placebo 2
• No serious adverse events reported in clinical trials 2

FDA-Approved Options (Recently Available)

Berdazimer gel 10.3% (Zelsuvmi) - First FDA-approved prescription medication for molluscum contagiosum 3

• Apply topically once daily for maximum 12 weeks 3
• Produces nitric oxide with antiviral properties affecting viral replication, inflammation, and immune control 3
• Supplied as two-tube system: berdazimer gel and hydrogel 3
• Common side effects localized to application site: burning, itching, redness, irritation 3
• Expected commercial availability in late 2024 3

Cantharidin 0.7% (VP-102/YCANTH) - FDA-approved drug-device combination 4

• Apply once every 21 days until complete clearance or up to 4 treatments maximum 4
• Achieves complete clearance in 46-54% of patients vs 13-18% with vehicle (P<0.001) 4
• Activates serine proteases causing blistering and inflammation, promoting infected cell shedding 4
• Adverse events mild to moderate: application site lesions, pruritus, pain 4

Alternative Topical Agents

Cantharidin (Compounded)

• Well-tolerated and effective when applied with or without occlusion 5
• 36.2% complete clearance vs 10.6% with placebo (P=0.0065) 5
• Mean lesion reduction of 17.4 lesions with cantharidin vs 5.1 with placebo (P=0.0033) 5
• No serious adverse events in clinical trials 5
• Note: Randomized controlled trial showed non-significant benefit in small study, though observational data supports efficacy 1

Topical Adapalene 0.1%

• Cost-effective over-the-counter option for periocular lesions 6
• Apply twice daily directly to eyelid lesions 6
• Rapid resolution of both eyelid involvement and associated follicular conjunctivitis 6
• No reported side effects in case series 6
• Particularly useful for periocular molluscum with conjunctivitis 6

Important Clinical Considerations

Treatment Rationale

Active treatment is strongly preferred over "watch and wait" approach despite potential for spontaneous resolution 7

• Reduces transmission risk to others 7
• Shortens infection duration (spontaneous resolution takes 6-12 months, up to 4 years) 1
• Decreases psychosocial sequelae (anxiety, embarrassment, isolation) 7

Treatments NOT Recommended

Imiquimod has no proven benefit - showed no superiority over placebo in randomized controlled trials 1

Special Populations

Immunocompromised patients (HIV, transplant recipients):

• Higher risk of diffuse, persistent MC 7
• Active treatment particularly important in this population 7
• Large, multiple lesions with minimal inflammation suggest immunocompromised state 1

Periocular lesions:

• Lesion removal indicated for symptomatic patients with conjunctivitis 1
• Conjunctivitis may require weeks to resolve after lesion elimination 1
• Consider topical adapalene 0.1% as first-line for convenience and safety 6

Common Pitfalls

• Avoid destructive methods on facial/periocular lesions - higher scarring risk 1
• Treat nascent lesions in patients with multiple lesions to reduce recurrence risk 1
• Do not rely on topical antivirals alone - not effective for molluscum contagiosum 1
• Cryotherapy carries risk of postinflammatory hyperpigmentation or scarring 1